W54011

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 532958

CAS#: 405098-33-1

Description: W54011 is a high affinity C5a receptor antagonist (Ki = 2.2 nM).W54011 inhibits C5a-induced generation of reactive superoxide species, chemotaxis and intracellular Ca2+ mobilization in human neutrophils (IC50 values are 1.6, 2.7 and 3.1 nM, respectively).


Price and Availability

Size
Price

Size
Price

Size
Price

W54011 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 532958
Name: W54011
CAS#: 405098-33-1
Chemical Formula: C30H36N2O2
Exact Mass: 456.2777
Molecular Weight: 456.63
Elemental Analysis: C, 78.91; H, 7.95; N, 6.13; O, 7.01


Synonym: W54011; W 54011; W-54011

IUPAC/Chemical Name: N-[(4-dimethylaminophenyl)methyl]-7-methoxy-N-(4-propan-2-ylphenyl)-1,2,3,4-tetrahydronaphthalene-1-carboxamide

InChi Key: DVYASSBBADJRAS-UHFFFAOYSA-N

InChi Code: InChI=1S/C30H36N2O2/c1-21(2)23-11-16-26(17-12-23)32(20-22-9-14-25(15-10-22)31(3)4)30(33)28-8-6-7-24-13-18-27(34-5)19-29(24)28/h9-19,21,28H,6-8,20H2,1-5H3

SMILES Code: O=C(C1CCCC2=C1C=C(OC)C=C2)N(CC3=CC=C(N(C)C)C=C3)C4=CC=C(C(C)C)C=C4


Technical Data

Appearance:
White to off-white solid powder.

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Giraud T, Rufas P, Chmilewsky F, Rombouts C, Dejou J, Jeanneau C, About I. Complement Activation by Pulp Capping Materials Plays a Significant Role in Both Inflammatory and Pulp Stem Cells' Recruitment. J Endod. 2017 May 17. pii: S0099-2399(17)30261-3. doi: 10.1016/j.joen.2017.02.016. [Epub ahead of print] PubMed PMID: 28527850.

2: Seow V, Lim J, Cotterell AJ, Yau MK, Xu W, Lohman RJ, Kok WM, Stoermer MJ, Sweet MJ, Reid RC, Suen JY, Fairlie DP. Receptor residence time trumps drug-likeness and oral bioavailability in determining efficacy of complement C5a antagonists. Sci Rep. 2016 Apr 20;6:24575. doi: 10.1038/srep24575. PubMed PMID: 27094554; PubMed Central PMCID: PMC4837355.

3: Zhang JX, Zha WS, Ye LP, Wang F, Wang H, Shen T, Wu CH, Zhu QX. Complement C5a-C5aR interaction enhances MAPK signaling pathway activities to mediate renal injury in trichloroethylene sensitized BALB/c mice. J Appl Toxicol. 2016 Feb;36(2):271-84. doi: 10.1002/jat.3179. Epub 2015 Jun 10. PubMed PMID: 26095957.

4: Sendler M, Beyer G, Mahajan UM, Kauschke V, Maertin S, Schurmann C, Homuth G, Völker U, Völzke H, Halangk W, Wartmann T, Weiss FU, Hegyi P, Lerch MM, Mayerle J. Complement Component 5 Mediates Development of Fibrosis, via Activation of Stellate Cells, in 2 Mouse Models of Chronic Pancreatitis. Gastroenterology. 2015 Sep;149(3):765-76.e10. doi: 10.1053/j.gastro.2015.05.012. Epub 2015 May 19. PubMed PMID: 26001927; PubMed Central PMCID: PMC4560830.

5: Chmilewsky F, Jeanneau C, Laurent P, About I. LPS induces pulp progenitor cell recruitment via complement activation. J Dent Res. 2015 Jan;94(1):166-74. doi: 10.1177/0022034514555524. Epub 2014 Oct 30. PubMed PMID: 25359783.

6: Chmilewsky F, Jeanneau C, Laurent P, About I. Pulp fibroblasts synthesize functional complement proteins involved in initiating dentin-pulp regeneration. Am J Pathol. 2014 Jul;184(7):1991-2000. doi: 10.1016/j.ajpath.2014.04.003. Epub 2014 May 9. PubMed PMID: 24814102.

7: Chmilewsky F, Jeanneau C, Laurent P, Kirschfink M, About I. Pulp progenitor cell recruitment is selectively guided by a C5a gradient. J Dent Res. 2013 Jun;92(6):532-9. doi: 10.1177/0022034513487377. Epub 2013 Apr 19. PubMed PMID: 23603337.

8: Nitta H, Wada Y, Kawano Y, Murakami Y, Irie A, Taniguchi K, Kikuchi K, Yamada G, Suzuki K, Honda J, Wilson-Morifuji M, Araki N, Eto M, Baba H, Imamura T. Enhancement of human cancer cell motility and invasiveness by anaphylatoxin C5a via aberrantly expressed C5a receptor (CD88). Clin Cancer Res. 2013 Apr 15;19(8):2004-13. doi: 10.1158/1078-0432.CCR-12-1204. Epub 2013 Jan 3. PubMed PMID: 23287562.

9: Itoh S, Takeshita K, Susuki C, Shige-Eda K, Tsuji T. Redistribution of P-selectin ligands on neutrophil cell membranes and the formation of platelet-neutrophil complex induced by hemodialysis membranes. Biomaterials. 2008 Jul;29(21):3084-90. doi: 10.1016/j.biomaterials.2008.04.018. Epub 2008 May 2. PubMed PMID: 18452987.

10: Hama H, Ono N, Abe M. [Study for an allergic inflammation model using human lungs and its pharmacological application]. Yakugaku Zasshi. 2007 Apr;127(4):721-7. Review. Japanese. PubMed PMID: 17409703.

11: Sumichika H, Sakata K, Sato N, Takeshita S, Ishibuchi S, Nakamura M, Kamahori T, Ehara S, Itoh K, Ohtsuka T, Ohbora T, Mishina T, Komatsu H, Naka Y. Identification of a potent and orally active non-peptide C5a receptor antagonist. J Biol Chem. 2002 Dec 20;277(51):49403-7. Epub 2002 Oct 15. PubMed PMID: 12384495.